MO38-5 Dipeptidyl peptidase-4 inhibitors and risk of gall bladder cancer in type 2 diabetes patients: A meta-analytic synthesis

Annals of Oncology ◽

10.1016/j.annonc.2021.05.662 ◽

2021 ◽

Vol 32 ◽

pp. S324

Author(s):

Md Azharuddin

Keyword(s):

Type 2 Diabetes ◽

Bladder Cancer ◽

Gall Bladder ◽

Dipeptidyl Peptidase ◽

Gall Bladder Cancer ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase‐4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients

Clinical Pharmacology & Therapeutics ◽

10.1002/cpt.2058 ◽

2020 ◽

Author(s):

Chen‐Yi Yang ◽

Wei‐Ann Lin ◽

Pei‐Fang Su ◽

Lun‐Jie Li ◽

Chun‐Ting Yang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cardiovascular Diseases ◽

Treatment Effects ◽

Dipeptidyl Peptidase ◽

Heterogeneous Treatment Effects ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Review for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v2/review4 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Decision letter for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Decision letter for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v1/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Review for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v1/review4 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease

Journal of Diabetes Investigation ◽

10.1111/jdi.12917 ◽

2018 ◽

Vol 10 (3) ◽

pp. 706-713 ◽

Author(s):

Munehiro Kitada ◽

Yoshio Ogura ◽

Kyoko Nitta ◽

Mizue Fujii ◽

Keizo Kanasaki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Kidney Disease ◽

Glucose Control ◽

Diabetic Kidney Disease ◽

Dipeptidyl Peptidase ◽

Diabetic Kidney ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Effect of dipeptidyl peptidase 4 inhibitors on cardiovascular events in type-2 diabetes patients with renal impairment: A systematic review and meta-analysis

Indian Journal of Endocrinology and Metabolism ◽

10.4103/ijem.ijem_568_19 ◽

2020 ◽

Vol 24 (2) ◽

pp. 143

Author(s):

Maneesha Khalse ◽

B Ganapathy

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Renal Impairment ◽

Cardiovascular Events ◽

Meta Analysis ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Review for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v2/review3 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Author response for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v2/response1 ◽

2020 ◽

Author(s):

Kåre I. Birkeland ◽

Johan Bodegard ◽

Amitava Banerjee ◽

Dae Jung Kim ◽

Anna Norhammar ◽

...

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Author Response ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Review for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v1/review3 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text